Cholinesterase Unit Establishment and Issuing of »Warning Cards« for Carriers of Suxamethonium Sensitive Serum Butyrylcholinesterase Variants by Branka Šurina et al.




and Issuing of »Warning Cards« for
Carriers of Suxamethonium Sensitive
Serum Butyrylcholinesterase
Variants
Branka [urina1, Dra`en Nosso 2, Zoran [iftar1, Zlata Flegar-Me{tri}1 and
Vera Simeon-Rudolf3
1 Institute of Clinical Chemistry, Clinical Hospital »Merkur«, Zagreb, Croatia
2 Department of Otorhinolaryngology, Clinical Hospital »Merkur«, Zagreb, Croatia
3 Institute for Medical Research and Occupational Health, Zagreb, Croatia
A B S T R A C T
Recognition of butyrylcholinesterase (EC 3.1.1.8) variants in human serum is essen-
tial to identify patients who may be susceptible to a prolonged reaction of suxamethonium
and mivacurium, short-acting muscle relaxants. Thus they can be given appropriate
advice along with their relatives who may be similarly affected. Therefore, Cholineste-
rase Unit for detection of individuals, carriers of inherited suxamethonium sensitive
butyrylcholinesterase variants was established at the Institute for Clinical Chemistry of
the Clinical Hospital »Merkur«, Zagreb, Croatia. A study was conducted on sera from
patients referred to the Unit. Butyrylcholinesterase variants were determined by mea-
suring the enzyme activity and inhibition by specific inhibitors in the sera of 384 pa-
tients and of the members of seven families. Cholinesterase Unit issued »Warning Cards«
to the carriers of inherited serum butyrylcholinesterase variants in order to avoid pro-
longed apnea that suxamethonium might cause.
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Introduction
Since the early thirties when two en-
zymes, acetylcholinesterase (AChE; ace-
tylcholine acetylhydrolase, EC 3.1.1.7) and
butyrylcholinesterase (BChE; acylcholine
acylhydrolase, EC 3.1.1.8) were recogni-
zed as being capable of hydrolyzing ace-
tylcholine, a very extensive research has
been conducted on their physiological and
pharmacological properties pertinent to
medical practice. Acetylcholinesterase,
specific for hydrolysis of acetylcholine
and closely related esters, is located in
nerves, muscles, erythrocytes and placen-
ta. Butyrylcholinesterase is located in the
central and peripheral nervous system,
liver and serum. The function of serum
BChE is the subject of several hypotheses
including its role in transmission of slow
nerve impulses, lipid metabolism and
choline homeostasis. BChE binds orga-
nophosphorus compounds (pesticides and
nerve agents) thus preventing inhibition
of AChE. Also, it has been shown that
BChE degrades several drugs as bam-
buterol, aspirin, cocaine and cocaine like
local anesthetics. The results of the re-
search of the nature of butryrylcholine-
sterase and its variants as well as their
role in the human body have been sum-
marized and discussed in several compre-
hensive reviews1–7.
At present our principal interest is in
butyrylcholinesterase in human serum
and its pharmacological properties to hy-
drolyze the short-acting muscle relaxant
suxamethonium. After suxamethonium
application inherited variants of human
serum butyrylcholinesterase were identi-
fied in about 65% of cases with prolonged
apnea as well as in some members of
their families8–11.
Suxamethonium (succinyldicholine) is
one of the muscle relaxants given to pa-
tients immediately before surgery, and it
is hydrolyzed by butyrylcholinesterase to
form succinylmonocholine and choline.
The usual (U) butyrylcholinesterase hy-
drolyses 90% of dose 1.0–1.5 mg/kg of
suxamethonium within 1–2 minutes, thus
restoring the normal neurotransmission
in the smooth muscles of the respiratory
tract. Atypical (A) variant of butyrylcho-
linesterase has a low affinity for suxa-
methonium and needs more time to hy-
drolyze the same dose of suxamethonium.
Suxamethonium binds to acetylcholine
receptors, blocks the transmission of ne-
uroimpulses causing prolonged apnea1–8.
The time to sufficient recovery of neuro-
muscular function following succinylcho-
line or mivacurium may be from one to
several hours, in extreme case up to 10
hours9–11. The other BChE variants, like
fluoride-resistant (F), silent (S), Kalow
(K) or J variant also have due to various
reasons, a reduced capability to hydro-
lyze suxamethonium. The usual BChE to-
gether with the variants give rise to fif-
teen phenotypes, which can be identified
by standard biochemical methods coupled
with family studies2,7,9,10. With our expe-
rience and research on cholinesterase12,13
as well as after our participation in the
»Cholinesterase Proficiency Program No
4« (the International Program for Quality
Control of Measurements of Serum Cho-
linesterase Activity and Phenotyping, or-
ganized by R. T. Evans from St. James’s
University Hospital, Leeds, UK, from
1993 to 1997)14,15, we decided to establish
the first Cholinesterase Unit in our coun-
try for detection of individuals, carriers of
atypical and other suxamethonium sensi-
tive butyrylcholinesterase variants. In
some Western countries similar units are
being set up to issue warning cards to the
patients and to establish a database of
persons with inherited butyrylcholineste-
rase variants.
The aim of this report is to present our
Cholinesterase Unit and results obtained
by phenotyping 384 patients and 7 of
their families as well as the need to issue
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»Warning Cards« to the carriers of suxa-
methonium sensitive BChE variants.
Patients were from the Department of
Otorhinolaryngology of the Clinical Hos-
pital »Merkur«, Zagreb.
Cholinesterase unit
Formation, organization and research
of the Cholinesterase Unit at the Insti-
tute of Clinical Chemistry, Merkur Clini-
cal Hospital, Zagreb, Croatia was started
in 2000. The main objectives of the Cho-
linesterase Unit are: (a) to establish the
first center for detection of individuals
and their families, carriers of an unusual
phenotype and/or genotype with butyryl-
cholinesterase variants, (b) to issue »Warn-
ing Cards« (in Croatian and English) to
individuals with butyrylcholinesterase va-
riants sensitive to suxamethonium and
mivacurium, (c) to establish a database of
family indexes for persons from the Re-
public of Croatia with inherited butyryl-
cholinesterase variants, considering expe-
riences of many other European countries
and on the basis of standard methodolo-
gies, (d) to organize the internal and ex-
ternal laboratory control of measuring
cholinesterase activity and phenotyping,
(e) to contact and invite anesthesiologists
(from Zagreb and other medical centers
and hospitals in Croatia) to report pa-
tients with long periods of apnea after
suxamethonium or mivacurium adminis-
tration and ask them to send blood sam-
ples for detection of BChE variants, (f) to
obtain reliable and accurate information
about the diagnosis, medical treatment,
anesthetic agents and information on rel-
atives, (g) to introduce DNA analysis and
BChE genotyping of blood samples.
Patients and Methods
We examined 384 patients ranging in
age 3–29 years, undergoing tonsillecto-
my, and 7 families of the patients who
were carriers of atypical or other suxa-
methonium sensitive BChE phenotypes.
Venous blood was collected into vacuta-
iner tubes (Becton Dickinson) without
anticoagulant. Estimation of butyrylcho-
linesterase activity and inhibitor num-
bers was done either on the fresh serum
or on the serum stored at –20 °C before
further use.
BChE activity was measured in sera
with 7.0 mM butyrylthiocholine as sub-
strate according to the spectrophotometric
method described by Das and Liddell16
using the Herbos diagnostics kit (Herbos,
Sisak, Croatia). The product of substrate
hydrolysis, thiocholine, reacts with DTNB
reagent (5,5’-dithiobis-2-nitrobenzoate) yiel-
ding a yellow anion 5-thio-2-nitrobenzoate.
The increase in absorbance was followed
for several minutes at 415 nm. The en-
zyme activity was expressed in the inter-
national unit (U/L) that corresponds to
micromoles of substrate hydrolyzed per
minute per liter of serum.
Phenotyping of BChE was done by
measuring the inhibition of butyrylthio-
choline hydrolysis by dibucaine, sodium
fluoride, urea or Ro 02-0683 (dimethyl-
carbamate of (2-hydroxy-5-phenyl-benzyl)-
trimethylammonium bromide)16–21. The
activity of enzyme was measured imme-
diately after the addition of dibucaine, so-
dium fluoride or urea and their final con-
centrations were 0.10 mM, 0.19 mM and
5.0 M, respectively. To determine the in-
hibition by R0 02-0683 serum was incu-
bated with 32 nM inhibitor for two hours
before the substrate was added. From the
degree of inhibition the inhibitor num-
bers (percent of inhibition) DN, FN, UN
and RoN for dibucaine, sodium fluoride,
urea and Ro 02-0683 were calculated.
BChE activity was measured on the VP
ABBOTT bichromatic analyzer at 30 °C22.
We standardized and controlled our me-
thodology during our participation in the
International Proficiency Program No 4.
for quality control of measurements of se-
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rum BChE activity and phenotyping pro-
vided in a period from 1993 to 199714,15.
The long-term analytical imprecision
for the BChE activity expressed as coeffi-
cient of variation was 1.5% and 2.5% for
normal and pathological activities, re-
spectively, and analytical inaccuracy ex-
pressed as the bias for normal and patho-
logical activities was 2.5%12.
Results
The frequency distribution of BChE
phenotypes determined on the basis of ac-
tivities and inhibitor numbers measured
in serum taken from patients, prior to
their undergoing tonsillectomy, is shown
in Table 1. The frequency of usual BChE
phenotype (Table 1) is similar to that pre-
sented in our previous studies of the Cro-
atian population12,13,23. Ranges of BChE
activities (U/L) for UU, UA, AA, UF and
AK phenotypes agree with those obtained
on 720 healthy individuals12 whom we
previously investigated using the same
methods22. Activities of UA, AA, AK and
AS phenotypes are significantly lower
than UU and UF. This is consistent with
other reports2,12,13,20. The US and AS phe-
notypes were detected which had not be-
en observed in our previous cohorts12,13,23.
Though we have found individuals
with the A, F, S or K variants (UA, UF,
US, AA, AK and AS) in 25 out of 384 pa-
tients (7%), we were only able to examine
7 families, 4 families of UA carriers and 1
family of each AS, US and AA carriers
(Table 2). So far we have issued »Warning
Cards« (Figure 1.) to two sisters of whom
one was assigned as an AK, and another
a UA phenotype carrier. For patients with
suxamethonium sensitive variants (Table
2) we did not officially receive documen-
ted reports but have got only personal
communications from medical doctors in
charge that the patients had signs of pro-
longed apnea following suxamethonium
applications.
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TABLE 1
DISTRIBUTION OF SERUM BCHE PHENOTYPES AND THE CORRESPONDING ACTIVITIES







Inhibitor numbers ± SD Activity ± SD
U/LDN FN UN RoN








































AA 1 0.3 22 85 97 11 2,868
AK 1 0.3 59 58 62 66 3,960
AS 1 0.3 23 78 92 15 1,111
Total 384 100.0
DN: dibucaine number; FN: fluoride number; UN urea number; RoN: Ro 02-0683 number. BChE
activities and inhibitor numbers are presented as the means with the standard deviation (SD)
and ranges in brackets.
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Fig. 1. Warning Card issued to a patient, who has a suxamethonium sensitive
butyrylcholinesterase phenotype.
Discussion
Although human serum BChE has no
known physiological function, it has an
important pharmacological property of
breaking down the short acting muscle
relaxants, suxamethonium (succinyldicho-
line, scoline) and mivacurium24. Detec-
tion of BChE variants which lack this
property is essential for the identification
of patients susceptible to prolonged pa-
ralysis in order to counsel them and any
close relatives who may be similarly af-
fected.
Summarizing our all results on the
Croatian population of 1545 individuals,
93% possessed only the usual enzyme.
The frequency for UA, UF, AK, AA, US,
AF, FF and AS phenotypes is 4.8, 1.5,
0.32, 0.32, 0.19, 0.13, 0.065 and 0.065, re-
spectively. On average 90% of the Euro-
pean population possess only the usual
BChE while 1 in 3500 individuals is ho-
mozygous for the atypical variant (AA)4,7.
On this basis one can predict that about
1300 persons in Croatia are likely to have
homozygous atypical BChE. Our value
for the atypical variant frequency might
be an overestimate because some individ-
uals were included into the cohort studied
due to their reaction to suxamethonium
rather than being chosen at random. It
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TABLE 2
DISTRIBUTION OF BCHE PHENOTYPES WITH CORRESPONDING ACTIVITIES AND INHIBITOR
NUMBERS IN 7 FAMILIES OF THE PATIENTS* WHO WERE SENSITIVE TO SUXAMETHONIUM.
Family 1 Family 2 Family 3 Family 4
Parent Child Parent Child Parent Child Parent Child
M F M F* M F M* F M F M* M* F M
BChE
Activity
7170 4284 7180 7105 6170 1922 2868 7680 6916 5309 6438 6420 5429 8471
DN 82 70 81 70 70 60 22 80 73 81 71 73 82 82
FN 54 59 56 60 60 63 85 52 54 49 55 55 48 51
UN 48 56 43 55 57 58 97 45 53 42 57 55 44 45
RoN 96 81 95 79 82 78 11 97 82 96 79 81 97 96
Phenotype UU UA UU UA UA UA AA UU UA UU UA UA UU UU
Family 5 Family 6 Family 7
Parent Child Parent Child Parent Child
M
(deceased)
F M F* M F M F* M F M F* F
BChE
Activity
4073 1019 1111 3583 2859 6515 555 6891 6792 8866 3960 4969
DN 81 25 23 80 79 80 89 81 72 82 59 74
FN 53 77 78 52 51 52 47 52 59 54 58 59
UN 47 92 92 45 40 45 44 43 53 46 62 54
RoN 96 20 15 99 97 99 100 96 83 97 66 85
Phenotype US AS AS US US UU US UU/UK UA UU AK UA
M – male, F – female
Phenotypes expecting to be sensitive to suxamethonium are in bold letters
has been reported that the atypical vari-
ant occurs more commonly in Mediterra-
nean regions than in the northern coun-
tries1,6,7 which might also be an additional
reason for somewhat higher frequency of
atypical allele in the Croatian population.
In addition to genetic abnormalities,
there are other causes of low BChE activ-
ities. Exposure to organophosphates or to
therapeutic and narcotic drugs like bam-
buterol and cocaine, disease, especially
that involving the liver, and pregnancy,
all reduce enzyme activity1,2,6. Low BChE
activity, either genetically inherited or
acquired, is unfavorable for individuals if
muscle relaxants like suxamethonium or
mivacurium should be administered. Many
studies show that an abnormal response
to a normal dose of succinylcholine is not
always caused by abnormal butyrylcho-
linesterase genotypes. The abnormal bu-
tyrylcholinesterase accounts for abnormal
response to succinylcholine only in 60% of
cases11. At present the screening of pati-
ents for low BChE activity prior to surgery
is justified if there is evidence of potential
risk. BChE analysis using molecular biol-
ogy at the DNA level can improve bio-
chemical diagnosis9–11. DNA analysis pro-
vides the precise location of nucleotide
alterations in the variants. However, DNA
sequencing is time consuming and still
not commonly implemented. Biochemical
analysis is reliable and provides suffi-
cient information on the BChE status10.
In circumstances when there are mass
casualties information on BChE status
might be valuable if facilities for provid-
ing artificial ventilation are limited.
Conclusion
The Cholinesterase Unit was estab-
lished to provide a central service for
determining inherited serum butyrylcho-
linesterase variants sensitive to suxame-
thonium or mivacurium and to detect in-
dividuals showing an abnormal response
to the compounds. Once established, the
genotype of BChE does not change during
the lifetime. Therefore, early detection of
this genetic abnormality is very impor-
tant for patients undergoing a surgical
procedure. The carriers of an abnormal
phenotype of BChE receive a »Warning
Card« as a permanent warning against
succinylcholine administration as well as
a warning to the members of the their
families to test their own phenotype of
BChE.
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UVO\ENJE »KARTICA UPOZORENJA« ZA NOSIOCE ABNORMALNIH
BChE VARIJANTI
S A @ E T A K
Prepoznavanje varijanti butirilkolinesteraze (E.C. 3.1.1.8) u ljudskom serumu po-
sebno je va`no kako bi se identificirao pacijent koji je osjetljiv na produljeno djelovanje
kratkodjeluju}ih mi{i}nih relaksansa, poput sukcinilkolina (suxamethonium, scoline-
hidroklorid) i mivakurija. Neke varijante butirilkolinesteraze veoma sporo hidroliziraju
sukcinilkolin i prilikom njihove aplikacije mo`e nastupiti produ`ena paraliza mi{i}a.
Ako se na vrijeme otkriju te nasljedne varijante u serumu, pacijent i njegovi ro|aci,
koji mogu biti sli~no osjetljivi, dobiti }e odgovaraju}i stru~ni savjet i izbje}i mogu}e
komplikacije. Stoga je u Zavodu za klini~ku kemiju Klini~ke bolnice Merkur osnovana
Jedinica za fenotipiranje butirilkolinesteraze s podacima o obiteljima kod kojih su do-
kazane uro|ene varijante serumske butirilkolinesteraze osjetljive na suxametonij. U
po~etnom istra`ivanju odre|ene su varijante i fenotip butirilkolinesteraze u serumima
384 pacijenata i 7 njihovih obitelji. Ustanovljene su »Kartice upozorenja« kao informa-
cija od va`ne medicinske naravi, a izdane su dvojici pacijenata s abnormalnim BChE
varijantama, da bi se upozorilo anesteziologa na mogu}nost ekspresije prolongirane
apnee prilikom primjene kratkodjeluju}ih mi{i}nih relaksansa.
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